These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30866035)

  • 1. Integrating Novel Targets and Precision Medicine Into Prostate Cancer Care-Part 1: The Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer.
    Considine B; Petrylak DP
    Oncology (Williston Park); 2019 Mar; 33(3):113-8. PubMed ID: 30866035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leading causes of castration-resistant prostate cancer.
    Lu M; Lu H; Kong Q
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision medicine for advanced prostate cancer.
    Mullane SA; Van Allen EM
    Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancing therapies in metastatic castration-resistant prostate cancer.
    Baciarello G; Gizzi M; Fizazi K
    Expert Opin Pharmacother; 2018 Nov; 19(16):1797-1804. PubMed ID: 30311804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer.
    Considine B; Petrylak DP
    Oncology (Williston Park); 2019 Apr; 33(4):128-31. PubMed ID: 30990564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel agents for castration-resistant prostate cancer: Early experience and beyond.
    Fujimoto N
    Int J Urol; 2016 Feb; 23(2):114-21. PubMed ID: 26311471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
    Cereda V; Formica V; Massimiani G; Tosetto L; Roselli M
    Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer.
    Thelen P; Wuttke W; Seidlová-Wuttke D
    J Steroid Biochem Mol Biol; 2014 Jan; 139():290-3. PubMed ID: 23872207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in the mechanism and drug development of castration-resistant prostate cancer.
    Zuo M; Xu X; Li T; Ge R; Li Z
    Future Med Chem; 2016 May; 8(7):765-88. PubMed ID: 27149562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials.
    Roviello G; Sigala S; Sandhu S; Bonetta A; Cappelletti MR; Zanotti L; Bottini A; Sternberg CN; Fox SB; Generali D
    Eur J Cancer; 2016 Jul; 61():111-21. PubMed ID: 27162152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer.
    Mayer MJ; Klotz LH; Venkateswaran V
    J Urol; 2017 Apr; 197(4):1068-1075. PubMed ID: 27984108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug therapies for metastatic castration-resistant prostate cancer.
    El-Bahesh E; Finianos A; Alfaraj A; Aragon-Ching JB
    Future Oncol; 2015; 11(17):2395-403. PubMed ID: 26274603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting molecular resistance in castration-resistant prostate cancer.
    Chandrasekar T; Yang JC; Gao AC; Evans CP
    BMC Med; 2015 Sep; 13():206. PubMed ID: 26329698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New therapies in metastatic castration resistant prostate cancer].
    Thibault C; Massard C
    Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
    Shiota M; Eto M
    Int J Urol; 2016 May; 23(5):360-9. PubMed ID: 27062039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].
    Basset V; Flamand V; Crouzet S; Ploussard G
    Prog Urol; 2013 Oct; 23 Suppl 1():S44-8. PubMed ID: 24314738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC.
    Giacinti S; Poti G; Roberto M; Macrini S; Bassanelli M; DI Pietro F; Aschelter AM; Ceribelli A; Ruggeri EM; Marchetti P
    Anticancer Res; 2018 Nov; 38(11):6029-6039. PubMed ID: 30396917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of castration-resistant (advanced) prostate cancer (CRPC): rationale, progress and future directions.
    Chopra S; Rashid P
    Aust Fam Physician; 2015 May; 44(5):302-5. PubMed ID: 26042402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.